109 related articles for article (PubMed ID: 11436501)
21. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2000). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Fujime M; Fujita K; Hirose T; Matsukawa M; Takahashi S; Kunishima Y; Igari J; Ogihara M; Ishibashi K; Oguri T; Shigeta S; Yamaguchi K; Matsumoto T; Kashitani F; Yoshida H; Imafuku Y; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Kitamura M; Takano Y; Matsuoka Y; Matsuda S; Sato S; Furuhama T; Kumon H; Monden K; Aoki S; Mochida C; Hirakata Y; Kohno S; Miyazaki Y; Tomono K
Jpn J Antibiot; 2002 Aug; 55(4):370-98. PubMed ID: 12378869
[TBL] [Abstract][Full Text] [Related]
22. [Antimicrobial activities of carbapenems and fourth generation cephems against clinically isolated strains].
Suzuki Y; Nishinari C; Endo H; Tamura C; Jinbo K
Jpn J Antibiot; 2001 Sep; 54(9):473-90. PubMed ID: 11729712
[TBL] [Abstract][Full Text] [Related]
23. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants.
Wiedemann B; Zühlsdorf M
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():197-205. PubMed ID: 2681124
[TBL] [Abstract][Full Text] [Related]
24. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380
[TBL] [Abstract][Full Text] [Related]
25. [Bactericidal activity of biapenem against various bacteria].
Hiraishi T; Miyata A; Hara T; Araake M; Ogawa H
Jpn J Antibiot; 2001 Dec; 54(12):581-95. PubMed ID: 11877858
[TBL] [Abstract][Full Text] [Related]
26. [In vitro activity of biapenem (BIPM) against clinically isolated respiratory pathogens in 1996-1998].
Watanabe A; Tokue Y; Takahashi H; Kikuchi T; Kobayashi T; Gomi K; Fujimura S; Yasui S; Nukiwa T; Shoji S; Honda Y
Jpn J Antibiot; 1999 Dec; 52(12):690-4. PubMed ID: 10695024
[TBL] [Abstract][Full Text] [Related]
27. CP0569, a new broad-spectrum injectable carbapenem. Part 1: synthesis and structure-activity relationships.
Aihara K; Kano Y; Shiokawa S; Sasaki T; Setsu F; Sambongi Y; Ishii M; Tohyama K; Ida T; Tamura A; Atsumi K; Iwamatsu K
Bioorg Med Chem; 2003 Aug; 11(16):3475-85. PubMed ID: 12878141
[TBL] [Abstract][Full Text] [Related]
28. [In vitro antibacterial activity of meropenem, a new carbapenem: European data].
Debbia EA; Marchese A; Pesce A; Schito GC
New Microbiol; 1995 Oct; 18 Suppl():1S-17S. PubMed ID: 8574928
[TBL] [Abstract][Full Text] [Related]
29. Bactericidal activity of meropenem and interactions with other antibiotics.
Ferrara A; Grassi G; Grassi FA; Piccioni PD; Gialdroni Grassi G
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():239-50. PubMed ID: 2808210
[TBL] [Abstract][Full Text] [Related]
30. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2003). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Matsukawa M; Kunishima Y; Watanabe K; Kobayashi Y; Uchida H; Matsuda S; Hirose T; Sato S; Shigeta S; Fujime M; Fujita K; Yamaguti O; Ishibashi K; Igari J; Suzutani T; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Furuya N; Murai M; Deguchi T; Ishihara S; Ooe H; Matsumoto T; Takahashi K; Nishikawa M; Naito S; Egashira T; Konishi T; Oka T; Kitamura M; Kohno S; Fukuhara Y; Hirakata Y; Kondo A; Matsuda J; Nakano M; Kamidono S; Suzuki Y; Arakawa S; Kumon H; Monden K
Jpn J Antibiot; 2005 Dec; 58(6):518-43. PubMed ID: 16521344
[TBL] [Abstract][Full Text] [Related]
31. [Nationwide sensitivity surveillance of ciprofloxacin and various parenteral antibiotics against bacteria isolated from patients with severe infections--the first Ciproxan IV special investigation in 2001].
Yamaguchi K; Ishii Y; Iinuma Y; Yamanaka K; Ichiyama S; Watanabe N; Uehara N; Kaku M; Kurokawa Y; Hayashi M; Hirakata Y
Jpn J Antibiot; 2003 Dec; 56(6):546-73. PubMed ID: 15007872
[TBL] [Abstract][Full Text] [Related]
32. [Survey of the sensitivities of clinical isolates to antibacterial agents (annual report)].
Igari J; Shibano T; Satou S; Inoue M; Kobayashi I; Takahashi A; Yomoda S; Nishino T; Oguri T; Watanabe N; Uehara N; Kumasaka K; Yoshida H; Imafuku Y; Kobayasi Y; Okada J; Tokuda K; Hirata Y; Nakasaki N; Hongo T; Kawaguchi R; Ohtaki Y; Sasaki T; Matsumoto N; Saeki H
Jpn J Antibiot; 1999 Apr; 52(4):279-91. PubMed ID: 10396685
[TBL] [Abstract][Full Text] [Related]
33. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1998). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Matsukawa M; Kunishima Y; Ogiwara M; Ishibashi K; Shigeta S; Watanabe J; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Takano Y; Miyagawa Y; Matsuda S; Sato S; Furuhama T; Fujime M; Fujita K; Kohno S; Igari J; Miyazaki Y; Izumikawa K; Yamaguchi T; Mochida C; Oguri T
Jpn J Antibiot; 2000 Apr; 53(4):201-33. PubMed ID: 10868300
[TBL] [Abstract][Full Text] [Related]
34. [Preclinical evaluation of meropenem, a new parenteral carbapenem].
Edwards JR
New Microbiol; 1995 Oct; 18 Suppl():19S-31S. PubMed ID: 8574929
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.
Koga T; Abe T; Inoue H; Takenouchi T; Kitayama A; Yoshida T; Masuda N; Sugihara C; Kakuta M; Nakagawa M; Shibayama T; Matsushita Y; Hirota T; Ohya S; Utsui Y; Fukuoka T; Kuwahara S
Antimicrob Agents Chemother; 2005 Aug; 49(8):3239-50. PubMed ID: 16048932
[TBL] [Abstract][Full Text] [Related]
36. Antibacterial effect of imipenem in vitro against important aerobic and anaerobic strains isolated from clinical specimens.
Klietmann W; Focht J; Nösner K
Chemioterapia; 1987 Aug; 6(4):243-50. PubMed ID: 3477332
[TBL] [Abstract][Full Text] [Related]
37. [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone].
Nomura N; Mitsuyama J; Furuta Y; Yamada H; Nakata M; Fukuda T; Yamada H; Takahata M; Minami S
Jpn J Antibiot; 2002 Aug; 55(4):412-39. PubMed ID: 12378871
[TBL] [Abstract][Full Text] [Related]
38. Bacteriostatic and bactericidal in-vitro activity of meropenem against clinical isolates, including Mycobacterium avium complex.
Inderlied CB; Lancero MG; Young LS
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():85-99. PubMed ID: 2808217
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic.
Harabe E; Kawai Y; Kanazawa K; Otsuki M; Nishino T
Drugs Exp Clin Res; 1992; 18(2):37-46. PubMed ID: 1644010
[TBL] [Abstract][Full Text] [Related]
40. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2003 Oct; 56(5):458-96. PubMed ID: 14692381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
